Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
doi: 10.1007/s00125-006-0141-7
As your weight loss progresses and abdominal fat decreases, you may need to transition to other sites or adjust your technique to maintain proper subcutaneous delivery
The programme spans multiple trials targeting distinct endpoints: On 21 May 2026 Eli Lilly reported topline results from TRIUMPH-1, the pivotal Phase 3 obesity trial and the programme's first Phase 3 efficacy readout: in 2,339 adults, mean weight loss at the 80-week primary endpoint reached 19.0% (4mg), 25.9% (9mg), and 28.3% (12mg) versus 2.2% for placebo (Eli Lilly investor release
H., & Ahmad, F
Summary: Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) showing promising early evidence for significant weight reduction, improved metabolic markers, and reduced liver fat, but it has not yet received MHRA or EMA approval
US$ 27.91
US$ 23.48
US$ 21.64
US$ 25.86
US$ 24.99
US$ 29.75
